Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesAmortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesChange in TaxesChange in TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesShare-based CompensationShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tandem Diabetes Care (TNDM) Capital Expenditures (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of Capital Expenditures readings, the most recent being $2.9 million for Q4 2025.

  • On a quarterly basis, Capital Expenditures fell 6.52% to $2.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $3.7 million, a 80.77% decrease, with the full-year FY2025 number at $3.7 million, down 80.77% from a year prior.
  • Capital Expenditures hit $2.9 million in Q4 2025 for Tandem Diabetes Care, up from -$8.3 million in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $29.8 million in Q4 2022 to a low of -$18.7 million in Q4 2023.
  • Median Capital Expenditures over the past 5 years was $2.9 million (2025), compared with a mean of $3.1 million.
  • The widest YoY moves for Capital Expenditures: up 33358.43% in 2022, down 2217.85% in 2022.
  • Tandem Diabetes Care's Capital Expenditures stood at $89000.0 in 2021, then skyrocketed by 33358.43% to $29.8 million in 2022, then plummeted by 162.66% to -$18.7 million in 2023, then skyrocketed by 116.45% to $3.1 million in 2024, then dropped by 6.52% to $2.9 million in 2025.
  • The last three reported values for Capital Expenditures were $2.9 million (Q4 2025), -$8.3 million (Q3 2025), and $6.2 million (Q2 2025) per Business Quant data.